GlassScriptPhysician profile
Timothy V Siepel
NPI 1053348599
$850.67
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $132 · 2021: $13.83 · 2022: $31.39.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $233.54 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $60.89 | 2019 | |
| Gilead Sciences, INC. | $59.63 | 2019 | |
| Sunovion Pharmaceuticals INC. | $55.84 | 2019 | |
| Lilly USA, LLC | $55.33 | 2019 | |
| Novo Nordisk INC | $45.81 | 2019-2020 | |
| Pfizer INC. | $42.13 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $39.77 | 2019-2020 | |
| Biotronik INC. | $34.04 | 2019 | |
| Amgen INC. | $33.22 | 2019-2020 | |
| Abbvie INC. | $31.39 | 2022 | |
| Amarin Pharma, INC. | $31.29 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.95 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $21.25 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.69 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.92 | 2019 | |
| Abbott Laboratories | $13.83 | 2021 | |
| Grifols USA, LLC | $13.43 | 2020 | |
| Seqirus USA INC | $11.68 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.04 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Siepel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.